Please send submissions for the eALERT to Sarah Keblin by 4 PM Wednesday for submission in the current week’s issue.

Thursday, October 30, 2014

VCC Research Symposium: November 21
VCC Member Retreat: November 14
Brovember launches November 1
Leunigs’ Event to Benefit Men’s Health and Cancer Efforts at the VCC

Clinical Trials News
Publications and Announcements
Funding Opportunities- NEW LISTING THIS WEEK

Ongoing Events

---

**Weekly Event Spotlight**

Tuesday, November 4
Biochemistry Seminar

**2014 VCC Clinical and Translational Research Symposium: Nov. 21**

Mark your calendar for the [2014 VCC Clinical and Translational Research Symposium](#) on **Friday, November 21, 2014**. This year’s all-day research meeting, taking place in Davis Auditorium, will be focused on *Molecular and Behavioral Cancer Epidemiology* and will cover a wide range of related topics.

For a look at the day’s full agenda [click here](#).
Daniel Bolon, PhD, UMASS Medical School

*Investigating molecular and evolutionary mechanism through protein fitness landscapes*

Given C443 12 PM to 1 PM

---

**Junior Investigators and Call for Posters**

Junior investigators will also be invited to speak and will be selected to do so from among those participants that submit posters for the day’s scientific poster presentation. The poster session is open to all attendees and poster topics do not need to directly correlate to the theme of the meeting. This will be a judged poster session with prizes offered in various categories. If you are interested in contributing a poster, please contact Charles Brooks. Junior investigators will be invited to speak based upon a qualified abstract; abstracts due by November 7th for consideration.

For more information about the event or submitting an abstract, click here, or contact Charles Brooks.

---

**October 2014**
*Breast Cancer Awareness Month*

31 **Biochemistry Seminar:** Investigating molecular and evolutionary mechanism through protein fitness landscapes, featuring Daniel Bolon, PhD, UMASS Medical School; Given C443, 12-1 PM.

---

**November 2014**
*Lung and Pancreatic Cancer Awareness Month*

4 **VCC Grand Rounds:** Med Ed 300, 8-9 AM.

7 **Biochemistry Seminar:** The Squid Giant Axon and Tau: A Classic System Tackles a New Problem, featuring Christopher Berger, PhD, UVM Dept. of Molecular Physiology and Biophysics; Given C443, 12 PM.

11 **VCC Grand Rounds:** The

---

**Fall 2014 VCC Member Retreat**

VCC members, please block your calendar for **Friday, November 14 from 12-5 PM** for the fall VCC Member Retreat. A calendar meeting request was sent via Outlook; if you do not use Outlook, please be sure to manually add this to your calendar. The event will take place in the
**Role of Src-family Kinases in Metastatic Progression**, Irwin H. Gelman, PhD, Roswell Park Cancer Institute; Reardon Classroom (Med Ed 300), 8-9 AM.

**Return of the MO--to Benefit the VCC!**

Gentleman, start thinking mustache! Once again, the Vermont Cancer Center, led by a group of dedicated providers, will be growing mustaches in November to raise awareness, and new this year--funds, for men’s health and cancer research efforts happening at the Vermont Cancer Center.

Included in this effort will be an all-day fundraiser hosted by Leunig's Bistro on November 16th where participants will be encouraged to come "show their MO".

Stay tuned for more information including how to join in the growing and fundraising efforts around what we’ll be calling here at the VCC, "Brovember"!

For more information please contact Manon O’Connor, Senior Director of Development for the Vermont Cancer Center.

---

*December 2014*

**14 VCC Member Retreat;**
for VCC members and staff only; 12-5 PM, Memorial Lounge, Waterman Building ; for more information please contact Charles Brooks.

**16 Leunig's Bistro Event to Benefit the VCC.**

**18 VCC Grand Rounds;**
Chronic Opiod Protocol presentation and practical training, featuring Carlos Pino, MD; Reardon Classroom (MedEd 300), 8-9 AM.

**18-21 AACR International Symposium on Molecular Targets and Cancer Therapeutics;**
Barcelona, Spain.

**21 VCC Clinical and Translational Research Symposium; Molecular and Behavioral Cancer Epidemiology;**
Davis Auditorium, Fletcher Allen Health Care, 8:00-4:30. RSVP to Charles Brooks.

---

**Vermont Cancer Center providers and researchers pose with Bob Conlon of Leunig's Bistro for a Brovember kick-off photo**

**Leunig's Bistro to Host November 16**
Fundraiser for Men's Cancer Research and Education at the VCC

In follow-up to their month-long efforts to raise funds and awareness for the High Risk Breast Program at the Vermont Cancer Center, Leunigs' Bistro, on Church Street in Burlington, will be hosting an all-day fundraiser on Sunday, November 16th. Proceeds from sales throughout the day will benefit men's health and cancer research and education efforts at the Vermont Cancer Center.

Mark your calendar and join other VCC members, staff and faculty for brunch, lunch or dinner!

For more information, please contact Manon O'Connor.

Clinical Trials News

Three New PARP Inhibitor Trials in Breast and Ovarian Cancer Patients with BRCA1 or BRCA2 Mutations

There are currently three PARP inhibitor trials available at Fletcher Allen Health Care for individuals with BRCA mutations. Two are for breast cancer patients, and one for ovarian cancer patients. The first breast trial is comparing the efficacy and tolerability of Olaparib (the PARP inhibitor) to the physician's choice between three different regimens (capecitabine, vinorelbine, or eribulin) for metastatic BRCA1/2 mutated patients. Potential participants should have received prior treatment with an anthracycline and taxane in either an adjuvant or metastatic setting and must be HER2 negative.

The second breast trial is a double-blind, placebo-controlled trial comparing the efficacy and tolerability of carboplatin and paclitaxel plus veliparib (the PARP inhibitor)/placebo for locally advanced and unresectable or metastatic BRCA1/2 mutated patients. Potential participants should not have received treatment with a taxane previously and must be HER2 negative.

The ovarian trial is a double-blind placebo-controlled trial looking at Olaparib monotherapy as a maintenance regimen in patients with ovarian cancer and BRCA mutations following first-line, platinum-based chemotherapy. These patients must have completed first line platinum therapy with clinical complete response or partial response and have no clinical evidence of disease progression on the post treatment scan nor a rise in CA-125.
All of these trials can be found on the Vermont Cancer Center website which contains contact information for each of the three studies.

For more information about the breast trials contact Hannah Eldred; for the ovarian trial contact Jen Holmes.

Click here to view a full listing of VCC clinical trials.

---

Publications and Announcements

*Please send announcements and publication notices to Sarah Keblin for inclusion in the weekly eALERT and other promotional material*

Announcements:

Matthew Wood, MD has been appointed to the Northern New England Clinical Oncology Society (NNECOS) Board of Directors.

Recent Publications by VCC Members:


---

Funding Opportunities
Green indicates NEW this week

- **College of Medicine Internal Grant Program and Bridge Support Program**: deadline for each is midnight, October 31, 2014.

- **NCI Centers of Cancer Nanotechnology Excellence (CCNEs)(U54)**: deadline for submission is November 3, 2014.

- **AACR Stand Up to Cancer Ovarian Cancer Research Fund, National Ovarian Cancer Coalition Translational Research Dream Team Grant**: deadline for letter of intent is November 7, 2014, 12 PM.

- **NSF Major Instrumentation (MRI) Program**: UVM may submit up to three proposals for instrumentation development and acquisition, maximum award is $4M; letter of intent should describe instrument development or acquisition for which support is sought, potential users of the instrument, plan for cost-sharing, and why proposed project would be competitive for award. Letter should also describe instrument's potential to support activities of one or more of the University's strategic initiatives. Letters should also include an endorsement from the appropriate Department Chair and Dean. Proposed projects will be evaluated using the following criteria: the two standard NSF criteria, Intellectual Merit and Broader Impacts; project alignment with the program goals; project feasibility strength; and thoroughness of the cost share plan letters of intent due to UVM's Hilda Alajian by November 10, 2014.

- **NCI New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01)**: LOI due 30 days before submission date of application; submission dates are Nov. 10, 2014 and July 8, 2015.

- **Bill and Melinda Gates Foundation Grand Challenges Explorations Awards**: seeking innovative global health and development solutions in any discipline; two page proposals being accepted from September 4 through November 12, 2014.

- **NCI Innovative Research in Cancer Nanotechnology (IRCN) (U01)**: deadline for submission
• **Damon Runyon Physician-Scientist Training Award**; four years of funding totaling $460,000 plus debt retirement up to $100,000; deadline for application is **Monday, December 1, 2014**.

• **2015 Kimmel Scholar and Translational Science Award**; $200K over two years for junior faculty research in cancer; application deadline is **December 3, 2014**.

• **UVM Reach Grants**; providing seed funding to promote innovative research, scholarship and creative arts at UVM; deadline for submission is **December 5, 2014**.

**VCC Internal Funding/Grants Available Click Here**

---

**Ongoing Events**

**Environmental Pathology and Carcinogenesis Seminar Series**  
Mondays at Noon, HSRF 200

**VCC Grand Rounds**  
1st, 2nd, 3rd, 5th  
Tuesday 8-9am, MedEd 300

Please refer to the VCC Website for information regarding regularly scheduled tumor board meetings. Information can be found [here](#).